Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

BACKGROUND: Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have eme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Dang, Kevin, Castello, Giulia, Clarke, Starlynn C, Li, Yuping, Balasubramani, Aarti, Boudreau, Andrew, Davison, Laura, Harris, Katherine E, Pham, Duy, Sankaran, Preethi, Ugamraj, Harshad S, Deng, Rong, Kwek, Serena, Starzinski, Alec, Iyer, Suhasini, van Schooten, Wim, Schellenberger, Ute, Sun, Wenchao, Trinklein, Nathan D, Buelow, Roland, Buelow, Ben, Fong, Lawrence, Dalvi, Pranjali
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183203/
https://ncbi.nlm.nih.gov/pubmed/34088740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados